Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)

Omnicell, Inc. (NASDAQ:OMCL) is one of the best small cap stocks to buy for 10x potential. Omnicell, Inc. (NASDAQ:OMCL) received several rating updates following the release of its financial results for fiscal Q1 2026 on April 28. Craig-Hallum lifted the price target on the stock to $55 from $53 on April 29, reiterating a Buy rating on the shares and stating that following the company’s beat and raise quarter, the firm believes there still exists room for shares to run. The firm further stated that it wants investors to focus on how Omnicell, Inc. (NASDAQ:OMCL) is positioning itself for the long term.

The company has raised its available units three times, given the strong demand for demos, and the firm believes this would allow more customers to see/feel the benefits of Titan. Craig-Hallum also believes that continued innovation around OmniSphere and other services should drive enterprise-wide adoption of the company’s solutions in the coming periods. The same day, KeyBanc also raised the price target on Omnicell, Inc. (NASDAQ:OMCL) to $70 from $60 while maintaining an Overweight rating on the shares.

Omnicell, Inc. (NASDAQ:OMCL) provides medication management automation solutions and adherence tools for healthcare systems and pharmacies. The company’s solutions include central pharmacy dispensing, intelligence, platform, interoperability, medication adherence, population health, and point of care automation.

While we acknowledge the risk and potential of OMCL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OMCL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.